Compare BTCT & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTCT | TCRT |
|---|---|---|
| Founded | 2006 | 1998 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 7.8M |
| IPO Year | 2019 | 2025 |
| Metric | BTCT | TCRT |
|---|---|---|
| Price | $0.56 | $1.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 253.5K | ★ 1.6M |
| Earning Date | 11-27-2026 | 11-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.66 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,900,000.00 |
| Revenue This Year | $1.58 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.43 | $0.72 |
| 52 Week High | $2.75 | $4.50 |
| Indicator | BTCT | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 34.27 | 44.64 |
| Support Level | $0.50 | $1.61 |
| Resistance Level | $1.21 | $2.09 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 4.48 | 10.16 |
BTC Digital Ltd is the ledger technology that underlies bitcoin and other cryptocurrencies, based in the U.S., with a focus on bitcoin mining. A blockchain is a decentralized, distributed, and encrypted digital public ledger that stores information in a secure, verifiable, and permanent way. The company also generates revenue through the resale of mining machines, mining machine rental, and miner hosting services.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.